• 1
    Rahman, A. and Isenberg, D. A., Systemic lupus erythematosus. N. Engl. J. Med. 2008. 358: 929939.
  • 2
    Flesher, D. L., Sun, X., Behrens, T. W., Graham, R. R. and Criswell, L. A., Recent advances in the genetics of systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2010. 6: 461479.
  • 3
    Morel, L., Genetics of SLE: evidence from mouse models. Nat. Rev. Rheumatol. 2010. 6: 348357.
  • 4
    Harley, I. T., Kaufman, K. M., Langefeld, C. D., Harley, J. B. and Kelly, J. A., Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 2009. 10: 285290.
  • 5
    Cohen, P. L. and Maldonado, M. A., Animal models for SLE. Curr. Protoc. Immunol. 2003. Chapter 15: Unit 15 20.
  • 6
    Sigurdsson, S., Nordmark, G., Goring, H. H., Lindroos, K., Wiman, A. C., Sturfelt, G., Jonsen, A. et al., Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 2005. 76: 528537.
  • 7
    Graham, R. R., Kozyrev, S. V., Baechler, E. C., Reddy, M. V., Plenge, R. M., Bauer, J. W., Ortmann, W. A. et al., A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 2006. 38: 550555.
  • 8
    Graham, R. R., Kyogoku, C., Sigurdsson, S., Vlasova, I. A., Davies, L. R., Baechler, E. C., Plenge, R. M. et al., Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. U.S.A. 2007. 104: 67586763.
  • 9
    Kelly, J. A., Kelley, J. M., Kaufman, K. M., Kilpatrick, J., Bruner, G. R., Merrill, J. T., James, J. A. et al., Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun. 2008. 9: 187194.
  • 10
    Demirci, F. Y., Manzi, S., Ramsey-Goldman, R., Minster, R. L., Kenney, M., Shaw, P. S., Dunlop-Thomas, C. M. et al., Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann. Hum. Genet. 2007. 71: 308311.
  • 11
    Shin, H. D., Kim, I., Choi, C. B., Lee, S. O., Lee, H. W. and Bae, S. C., Different genetic effects of interferon regulatory factor 5 (IRF5) polymorphisms on systemic lupus erythematosus in a Korean population. J. Rheumatol. 2008. 35: 21482151.
  • 12
    Kozyrev, S. V., Lewen, S., Reddy, P. M., Pons-Estel, B., Witte, T., Junker, P., Laustrup, H. et al., Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum. 2007. 56: 12341241.
  • 13
    Sigurdsson, S., Goring, H. H., Kristjansdottir, G., Milani, L., Nordmark, G., Sandling, J. K., Eloranta, M. L. et al., Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum. Mol. Genet. 2008. 17: 872881.
  • 14
    Feng, D., Stone, R. C., Eloranta, M. L., Sangster-Guity, N., Nordmark, G., Sigurdsson, S., Wang, C. et al., Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2010. 62: 562573.
  • 15
    Barnes, B. J., Moore, P. A. and Pitha, P. M., Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 2001. 276: 2338223390.
  • 16
    Barnes, B. J., Kellum, M. J., Field, A. E. and Pitha, P. M., Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol. 2002. 22: 57215740.
  • 17
    Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Kano, S. et al., Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005. 434: 243249.
  • 18
    Schoenemeyer, A., Barnes, B. J., Mancl, M. E., Latz, E., Goutagny, N., Pitha, P. M., Fitzgerald, K. A. et al., The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem. 2005. 280: 1700517012.
  • 19
    Yasuda, K., Richez, C., Maciaszek, J. W., Agrawal, N., Akira, S., Marshak-Rothstein, A. and Rifkin, I. R., Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFNregulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 2007. 178: 68766885.
  • 20
    Kyogoku, C. and Tsuchiya, N., A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun. 2007. 8: 445455.
  • 21
    Kozyrev, S. V. and Alarcon-Riquelme, M. E., The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 2007. 40: 591601.
  • 22
    Niewold, T. B., Kelly, J. A., Flesch, M. H., Espinoza, L. R., Harley, J. B. and Crow, M. K., Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008. 58: 24812487.
  • 23
    Richez, C., Yasuda, K., Bonegio, R. G., Watkins, A. A., Aprahamian, T., Busto, P., Richards, R. J. et al., IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J. Immunol. 2010. 184: 796806.
  • 24
    Savitsky, D. A., Yanai, H., Tamura, T., Taniguchi, T. and Honda, K., Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc. Natl. Acad. Sci. U.S.A. 2010. 107: 1015410159.
  • 25
    Reeves, W. H., Lee, P. Y., Weinstein, J. S., Satoh, M. and Lu, L., Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009. 30: 455464.
  • 26
    Chowdhary, V. R., Grande, J. P., Luthra, H. S. and David, C. S., Characterization of haemorrhagic pulmonary capillaritis: another manifestation of pristane-induced lupus. Rheumatology (Oxford) 2007. 46: 14051410.
  • 27
    Satoh, M. and Reeves, W. H., Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J. Exp. Med. 1994. 180: 23412346.
  • 28
    Satoh, M., Richards, H. B., Shaheen, V. M., Yoshida, H., Shaw, M., Naim, J. O., Wooley, P. H. et al., Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin. Exp. Immunol. 2000. 121: 399405.
  • 29
    Hamilton, K. J., Satoh, M., Swartz, J., Richards, H. B. and Reeves, W. H., Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin. Immunol. Immunopathol. 1998. 86: 271279.
  • 30
    Azeredo da Silveira, S., Kikuchi, S., Fossati-Jimack, L., Moll, T., Saito, T., Verbeek, J. S., Botto, M. et al., Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J. Exp. Med. 2002. 195: 665672.
  • 31
    Nacionales, D. C., Kelly-Scumpia, K. M., Lee, P. Y., Weinstein, J. S., Lyons, R., Sobel, E., Satoh, M. et al., Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007. 56: 37703783.
  • 32
    Nacionales, D. C., Weinstein, J. S., Yan, X. J., Albesiano, E., Lee, P. Y., Kelly-Scumpia, K. M., Lyons, R. et al., B-cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus. J. Immunol. 2009. 182: 42264236.
  • 33
    Lien, C., Fang, C. M., Huso, D., Livak, F., Lu, R. and Pitha, P. M., Critical role of IRF-5 in regulation of B-cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 2010. 107: 46644668.
  • 34
    Takahashi, S., Fossati, L., Iwamoto, M., Merino, R., Motta, R., Kobayakawa, T. and Izui, S., Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 1996. 97: 15971604.
  • 35
    Richards, H. B., Satoh, M., Jennette, J. C., Croker, B. P., Yoshida, H. and Reeves, W. H., Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 2001. 60: 21732180.
  • 36
    Wong, C. K., Ho, C. Y., Li, E. K. and Lam, C. W., Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000. 9: 589593.
  • 37
    Peng, S. L., Moslehi, J. and Craft, J., Roles of interferon-gamma and interleukin-4 in murine lupus. J. Clin. Invest. 1997. 99: 19361946.
  • 38
    Richards, H. B., Satoh, M., Shaw, M., Libert, C., Poli, V. and Reeves, W. H., Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 1998. 188: 985990.
  • 39
    Goldman, M., Druet, P. and Gleichmann, E., TH2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity. Immunol. Today 1991. 12: 223227.
  • 40
    Llorente, L., Zou, W., Levy, Y., Richaud-Patin, Y., Wijdenes, J., Alcocer-Varela, J., Morel-Fourrier, B. et al., Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 1995. 181: 839844.
  • 41
    Xu, Q., Katakura, Y., Yamashita, M., Fang, S., Tamura, T., Matsumoto, S. E., Aiba, Y. et al., IL-10 augments antibody production in in vitro immunized lymphocytes by inducing a Th2-type response and B-cell maturation. Biosci. Biotechnol. Biochem. 2004. 68: 22792284.
  • 42
    Yanai, H., Chen, H. M., Inuzuka, T., Kondo, S., Mak, T. W., Takaoka, A., Honda, K. et al., Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl. Acad. Sci. U.S.A. 2007. 104: 34023407.
  • 43
    Hua, J., Kirou, K., Lee, C. and Crow, M. K., Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006. 54: 19061916.
  • 44
    Lee, P. Y., Weinstein, J. S., Nacionales, D. C., Scumpia, P. O., Li, Y., Butfiloski, E., van Rooijen, N. et al., A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 2008. 180: 51015108.
  • 45
    Lee, P. Y., Kumagai, Y., Li, Y., Takeuchi, O., Yoshida, H., Weinstein, J., Kellner, E. S. et al., TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J. Exp. Med. 2008. 205: 29953006.
  • 46
    Ehlers, M., Fukuyama, H., McGaha, T. L., Aderem, A. and Ravetch, J. V., TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 2006. 203: 553561.
  • 47
    Peng, S. L., Szabo, S. J. and Glimcher, L. H., T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl. Acad. Sci. U.S.A. 2002. 99: 55455550.
  • 48
    Kawai, T. and Akira, S., TLR signaling. Semin. Immunol. 2007. 19: 2432.
  • 49
    McHeyzer-Williams, L. J. and McHeyzer-Williams, M. G., Antigen-specific memory B-cell development. Annu. Rev. Immunol. 2005. 23: 487513.
  • 50
    Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N. et al., The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1994. 1: 167178.
  • 51
    Coffman, R. L., Seymour, B. W., Lebman, D. A., Hiraki, D. D., Christiansen, J. A., Shrader, B., Cherwinski, H. M. et al., The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. Immunol. Rev. 1988. 102: 528.
  • 52
    Wen, X., Zhang, D., Kikuchi, Y., Jiang, Y., Nakamura, K., Xiu, Y., Tsurui, H. et al., Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B-cell chronic lymphocytic leukemia in a model of murine lupus. Eur. J. Immunol. 2004. 34: 27402749.
  • 53
    Del Prete, G., The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int. Rev. Immunol. 1998. 16: 427455.
  • 54
    Akahoshi, M., Nakashima, H., Tanaka, Y., Kohsaka, T., Nagano, S., Ohgami, E., Arinobu, Y. et al., Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 1999. 42: 16441648.
  • 55
    Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F. and Tough, D. F., Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001. 14: 461470.
  • 56
    Boonstra, A., Rajsbaum, R., Holman, M., Marques, R., Asselin-Paturel, C., Pereira, J. P., Bates, E. E. et al., Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 2006. 177: 75517558.
  • 57
    Palucka, A. K., Blanck, J. P., Bennett, L., Pascual, V. and Banchereau, J., Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 2005. 102: 33723377.
  • 58
    Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., Hussell, T. et al., IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011. 12: 231238.
  • 59
    Thibault, D. L., Chu, A. D., Graham, K. L., Balboni, I., Lee, L. Y., Kohlmoos, C, Landrigan, A et al.,IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J. Clin. Invest. 2008. 118: 14171426.
  • 60
    Purtha,W. E., Swiecki, M., Colonna,M, Diamond, M. S., Bhattacharya, D. Spontaneous mutation of the Dock2 gene in Irf5−/− mice complicates interpretation of type I interferon production and antibody responses. Proc. Natl. Acad. Sci. U.S.A. 2012. 109: E898904.